DEFA14A: Carisma Seeks Reverse Split to Maintain Nasdaq Listing

Carisma Therapeutics Inc. seeks stockholder approval for a reverse stock split to meet Nasdaq listing requirements and facilitate its merger with OrthoCellix.

Summary

• Carisma Therapeutics Inc. is holding a Special Meeting of Stockholders on August 5, 2025, at 10:00 a.m. Eastern Time to vote on a reverse stock split.
• The proposed reverse stock split is necessary for Carisma to comply with Nasdaq Capital Market listing criteria and avoid delisting.
• Carisma previously disclosed on June 23, 2025, that it entered into a Merger Agreement on June 22, 2025, with Ocugen, Inc. and its wholly-owned subsidiary, OrthoCellix, Inc.
• The Merger involves Carisma's wholly-owned subsidiary, Azalea Merger Sub, Inc., merging with and into OrthoCellix, with OrthoCellix continuing as Carisma's wholly-owned subsidiary.
• A Registration Statement on Form S-4, containing further information about OrthoCellix and the proposed Merger, was filed with the SEC on July 21, 2025.
• The reverse stock split is likely required to increase Carisma's common stock price to meet the minimum closing price for filing an initial listing application with Nasdaq in connection with the contemplated Merger.
• A separate special meeting of stockholders will be required to obtain the necessary approvals to complete the Merger and related matters.

Sentiment

Score: 4

Explanation: The sentiment is mixed to slightly negative. While the merger is a strategic positive, the immediate need for a reverse stock split due to Nasdaq compliance issues (implying a low stock price) is a significant negative indicator of current market performance.

Positives

• The proposed reverse stock split aims to ensure continued listing on the Nasdaq Capital Market, preventing a potential delisting.
• The ongoing merger with OrthoCellix, a subsidiary of Ocugen, represents a strategic corporate action that could enhance the company's future prospects and pipeline.

Negatives

• The necessity of a reverse stock split indicates that Carisma's common stock price is currently below Nasdaq's minimum listing requirements, reflecting poor market performance.
• The company faces the risk of delisting if the reverse stock split is not approved or does not effectively raise the stock price to meet compliance.

Risks

• Risk of delisting from the Nasdaq Capital Market if the reverse stock split is not authorized or fails to achieve the required minimum stock price.
• Risks associated with the completion of the proposed merger with OrthoCellix, including obtaining necessary stockholder approvals and satisfying other conditions.

Future Outlook

The company anticipates completing the merger with OrthoCellix, which will require a separate special meeting of stockholders for approval. The reverse stock split is a prerequisite to meet Nasdaq listing requirements for the combined entity.

Management Comments

• "YOUR VOTE IS IMPORTANT TO US. WHETHER OR NOT YOU PLAN TO ATTEND THE SPECIAL MEETING ONLINE, WE URGE YOU TO VOTE YOUR SHARES BY SUBMITTING YOUR PROXY OVER THE INTERNET OR BY TELEPHONE, OR BY COMPLETING, DATING, SIGNING AND RETURNING THE PROXY CARD."
• "YOUR PARTICIPATION IS IMPORTANT. PLEASE VOTE YOUR SHARES AS SOON AS POSSIBLE TO ALLOW US TO COMPLETE THE PROPOSED REVERSE STOCK SPLIT."

Industry Context

This filing reflects common challenges faced by smaller biotechnology companies, including maintaining stock exchange listings amidst fluctuating market valuations and pursuing strategic mergers to enhance pipeline and market position. The merger with Ocugen's subsidiary, OrthoCellix, indicates a trend towards consolidation and strategic partnerships within the biotech sector to leverage complementary assets and resources.

Stakeholder Impact

• Shareholders: Will be directly impacted by the reverse stock split, which will reduce the number of shares outstanding and increase the per-share price. Their ownership percentage will remain the same, but the nominal value of their shares will change. The merger will also significantly alter the company's structure and future prospects.
• Employees: Potential impacts from the merger, including integration of teams and changes in corporate structure.
• Customers/Partners: Potential changes in product focus or service offerings post-merger.

Next Steps

• Hold the Special Meeting of Stockholders on August 5, 2025, to vote on the reverse stock split.
• Hold a separate special meeting of stockholders to obtain approval for the Merger with OrthoCellix and related matters.
• Complete the Merger with OrthoCellix, subject to satisfaction or waiver of conditions.

Key Dates

Recommendation

The company is undergoing significant structural changes, including a necessary reverse stock split to maintain its Nasdaq listing and a strategic merger. While the reverse split addresses a critical compliance issue, the underlying reason (low stock price) is a concern. The merger introduces new potential but also integration risks. A seasoned investor would likely hold to observe the outcome of the reverse split, the completion of the merger, and the performance of the combined entity before making a definitive buy or sell decision.

Keywords

Carisma Therapeutics, Reverse Stock Split, Nasdaq Listing, SEC Filing, Merger Agreement, Ocugen, OrthoCellix, Corporate Governance, Stockholder Meeting, Biotechnology